Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- OCUL
- Price
- 11.12
- Stock movement down
- -0.30 (-2.63%)
- Company name
- Ocular Therapeutix Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.37B
- Ent value
- 2.18B
- Price/Sales
- 42.47
- Price/Book
- 9.17
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -8.51%
- 1 year return (CAGR)
- 37.45%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
OCUL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 42.47 |
| Price to Book | 9.17 |
| EV to Sales | 39.03 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 213.05M |
| EPS (TTM) | -1.36 |
| FCF per share (TTM) | -1.08 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 55.78M |
| Gross profit (TTM) | 49.57M |
| Operating income (TTM) | -250.83M |
| Net income (TTM) | -249.67M |
| EPS (TTM) | -1.36 |
| EPS (1y forward) | -1.48 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 88.87% |
| Operating margin (TTM) | -449.66% |
| Profit margin (TTM) | -447.58% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 344.77M |
| Net receivables | 30.77M |
| Total current assets | 386.98M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 22.29M |
| Total assets | 410.88M |
| Accounts payable | 6.26M |
| Short/Current long term debt | 77.01M |
| Total current liabilities | 49.29M |
| Total liabilities | 152.65M |
| Shareholder's equity | 258.23M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -190.06M |
| Capital expenditures (TTM) | 9.37M |
| Free cash flow (TTM) | -199.44M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -96.69% |
| Return on Assets | -60.77% |
| Return on Invested Capital | -75.29% |
| Cash Return on Invested Capital | -60.14% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.45 |
| Daily high | 11.55 |
| Daily low | 11.10 |
| Daily Volume | 3.71M |
| All-time high | 43.27 |
| 1y analyst estimate | 24.17 |
| Beta | 0.96 |
| EPS (TTM) | -1.36 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 9 Mar 2026 |
Downside potential
Loading...
Downside potential data
| OCUL | S&P500 | |
| Current price drop from All-time high | -74.30% | -0.89% |
| Highest price drop | -86.31% | -19.00% |
| Date of highest drop | 3 Mar 2025 | 8 Apr 2025 |
| Avg drop from high | -76.91% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.37B
Marketcap category
Mid-cap
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Employees
274
Website
Investor relations
-
SEC filings
CEO
Antony Mattessich
Country
USA
City
Bedford
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page